Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Cash (2019 - 2025)

Historic Change in Cash for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$222.9 million.

  • Kymera Therapeutics' Change in Cash fell 61779.18% to -$222.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 9246.0%. This contributed to the annual value of $10.3 million for FY2024, which is 7509.7% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Change in Cash stood at -$222.9 million, which was down 61779.18% from $245.9 million recorded in Q2 2025.
  • Kymera Therapeutics' Change in Cash's 5-year high stood at $245.9 million during Q2 2025, with a 5-year trough of -$222.9 million in Q3 2025.
  • Over the past 5 years, Kymera Therapeutics' median Change in Cash value was $9.5 million (recorded in 2024), while the average stood at $4.5 million.
  • In the last 5 years, Kymera Therapeutics' Change in Cash skyrocketed by 122740.24% in 2021 and then tumbled by 147086.86% in 2024.
  • Kymera Therapeutics' Change in Cash (Quarter) stood at -$104.3 million in 2021, then rose by 16.36% to -$87.2 million in 2022, then surged by 133.16% to $28.9 million in 2023, then crashed by 66.99% to $9.5 million in 2024, then plummeted by 2434.27% to -$222.9 million in 2025.
  • Its Change in Cash stands at -$222.9 million for Q3 2025, versus $245.9 million for Q2 2025 and -$30.3 million for Q1 2025.